Circulating proteins as predictive and prognostic biomarkers in breast cancer - Archive ouverte HAL Access content directly
Journal Articles Clinical Proteomics Year : 2022

Circulating proteins as predictive and prognostic biomarkers in breast cancer

Abstract

Abstract Breast cancer (BC) is the most common cancer and among the leading causes of cancer death in women. It is a heterogeneous group of tumours with numerous morphological and molecular subtypes, making predictions of disease evolution and patient outcomes difficult. Therefore, biomarkers are needed to help clinicians choose the best treatment for each patient. For the last years, studies have increasingly focused on biomarkers obtainable by liquid biopsy. Circulating proteins (from serum or plasma) can be used for inexpensive and minimally invasive determination of disease risk, early diagnosis, treatment adjusting, prognostication and disease progression monitoring. We provide here a review of the main published studies on serum proteins in breast cancer and elaborate on the potential of circulating proteins to be predictive and/or prognostic biomarkers in breast cancer.

Dates and versions

hal-03721274 , version 1 (12-07-2022)

Identifiers

Cite

Hugo Veyssière, Yannick Bidet, Frederique Penault-Llorca, Nina Radosevic-Robin, Xavier Durando. Circulating proteins as predictive and prognostic biomarkers in breast cancer. Clinical Proteomics, 2022, 19 (1), pp.25. ⟨10.1186/s12014-022-09362-0⟩. ⟨hal-03721274⟩
61 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More